Inclusion Criteria : 
  1.  HER2 positive recurrent or metastasis breast cancer . 
  2.  Patients with measurable disease are eligible . 
  3.  Eastern Cooperative Oncology Group ( ECOG ) performance status 0 or 1. 
  4.  Adequate organ function . 
  5.  Signed , written inform consent obtained prior to any study procedure . 
Exclusion Criteria : 
  1.  History of anti - cancer therapy for MBC （ with the exception of one prior hormonal regimen for MBC） . 
  2.  History of HER tyrosine kinase inhibitors or monoclonal antibody for breast cancer in any treatment setting ， except trastuzumab used in the neo - adjuvant or adjuvant setting . 
  3.  Assessed by the investigator to be unable receive systemic chemotherapy . 
  4.  History of other malignancy within the last 5 years ， except for carcinoma in situ of cervix ， basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent . 
  5.  Pregnant or lactating women ， or for women of childbearing potential unwilling to use a highly - effective contraception during of the study treatment and for at least 7 months after the last dose of study treatment.